Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study

Zaldy Sy Tan, Sudha Seshadri, Alexa Beiser, Peter W.F. Wilson, Douglas P. Kiel, Michael Tocco, Ralph B. D'Agostino, Philip A. Wolf

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Background: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. Results: Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, 0.87-1.04) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). Conclusion: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD.

Original languageEnglish (US)
Pages (from-to)1053-1057
Number of pages5
JournalArchives of Internal Medicine
Volume163
Issue number9
DOIs
StatePublished - May 12 2003
Externally publishedYes

Fingerprint

Alzheimer Disease
Cholesterol
Apolipoproteins E
Confidence Intervals
Serum
Population
Coronary Disease
Dementia
Body Mass Index
Cohort Studies
Smoking
Stroke
Genotype
Outcome Assessment (Health Care)
Weights and Measures

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study. / Tan, Zaldy Sy; Seshadri, Sudha; Beiser, Alexa; Wilson, Peter W.F.; Kiel, Douglas P.; Tocco, Michael; D'Agostino, Ralph B.; Wolf, Philip A.

In: Archives of Internal Medicine, Vol. 163, No. 9, 12.05.2003, p. 1053-1057.

Research output: Contribution to journalArticle

Tan, ZS, Seshadri, S, Beiser, A, Wilson, PWF, Kiel, DP, Tocco, M, D'Agostino, RB & Wolf, PA 2003, 'Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study', Archives of Internal Medicine, vol. 163, no. 9, pp. 1053-1057. https://doi.org/10.1001/archinte.163.9.1053
Tan, Zaldy Sy ; Seshadri, Sudha ; Beiser, Alexa ; Wilson, Peter W.F. ; Kiel, Douglas P. ; Tocco, Michael ; D'Agostino, Ralph B. ; Wolf, Philip A. / Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study. In: Archives of Internal Medicine. 2003 ; Vol. 163, No. 9. pp. 1053-1057.
@article{eaa9b9c714114a9fb23faa2d58ebab66,
title = "Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study",
abstract = "Background: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. Results: Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95{\%} confidence interval, 0.87-1.04) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95{\%} confidence interval, 0.90-1.05). Conclusion: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD.",
author = "Tan, {Zaldy Sy} and Sudha Seshadri and Alexa Beiser and Wilson, {Peter W.F.} and Kiel, {Douglas P.} and Michael Tocco and D'Agostino, {Ralph B.} and Wolf, {Philip A.}",
year = "2003",
month = "5",
day = "12",
doi = "10.1001/archinte.163.9.1053",
language = "English (US)",
volume = "163",
pages = "1053--1057",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Plasma total cholesterol level as a risk factor for Alzheimer disease the framingham study

AU - Tan, Zaldy Sy

AU - Seshadri, Sudha

AU - Beiser, Alexa

AU - Wilson, Peter W.F.

AU - Kiel, Douglas P.

AU - Tocco, Michael

AU - D'Agostino, Ralph B.

AU - Wolf, Philip A.

PY - 2003/5/12

Y1 - 2003/5/12

N2 - Background: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. Results: Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, 0.87-1.04) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). Conclusion: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD.

AB - Background: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. Results: Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, 0.87-1.04) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). Conclusion: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD.

UR - http://www.scopus.com/inward/record.url?scp=0037992873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037992873&partnerID=8YFLogxK

U2 - 10.1001/archinte.163.9.1053

DO - 10.1001/archinte.163.9.1053

M3 - Article

VL - 163

SP - 1053

EP - 1057

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 9

ER -